Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
August 18, 2020
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
August 11, 2020
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Application
Filed:
February 19, 2020
Publication date:
June 25, 2020
Applicant:
Acceleron Pharma Inc.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
October 11, 2018
Date of Patent:
June 23, 2020
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
Type:
Grant
Filed:
November 21, 2014
Date of Patent:
June 16, 2020
Assignees:
THE BRINGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.
Inventors:
Paul Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.
Type:
Application
Filed:
September 5, 2019
Publication date:
May 28, 2020
Applicant:
Acceleron Pharma Inc.
Inventors:
Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
October 29, 2015
Date of Patent:
March 31, 2020
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
Abstract: The present invention discloses heterodimers comprising endoglin-Fc and ALKI-Fc, or hetero dimers comprising endoglin-Fc and ALK2-Fc. The Fe domains can include amino acid mutations that promote heterodimer formation. In certain aspects, the disclosure provides heteromeric polypeptide complexes comprising a co-receptor of the TGF-beta superfamily and an extracellular domain of a type I serine/threonine kinase receptor of the TGF beta superfamily, an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta superfamily, or an additional co-receptor of the TGF-beta superfamily. In some embodiments, the disclosure provides heteromultimers comprising a ligand-domain of one or more co-receptor selected from: endoglin, Cripto-1, Cryptic, Cryptic family protein IB, CRIMI, CRIM2, BAMBI, BMPER, RGM-A, RGMB, hemojuvelin, betaglycan, and MuSK.
Type:
Application
Filed:
July 6, 2017
Publication date:
March 5, 2020
Applicant:
Acceleron Pharma Inc.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay
Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
Type:
Grant
Filed:
April 21, 2017
Date of Patent:
December 10, 2019
Assignees:
Acceleron Pharma Inc., Adimab, LLC
Inventors:
John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
October 27, 2016
Date of Patent:
August 13, 2019
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
July 23, 2019
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
July 9, 2019
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
September 25, 2017
Date of Patent:
June 11, 2019
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
June 4, 2019
Assignees:
Acceleron Pharma Inc., Adimab, LLC
Inventors:
Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay